With over 95% of new drugs failing Phase II and Phase III clinical trials due to a lack of efficacy and biomarker discovery, new translational technologies are required to make the oncology drug development process more efficient, to lower developmental costs, and to reduce attrition rates.
CrownBio provides a preclinical Translational Oncology Technology Platform utilizing the largest collection of PDX models (HuPrime® and HuKemia®). Our well characterized and predictive models are ideal to use in a mouse clinical trials (HuTrial) setting to identify and understand which patients will benefit from treatment before entering the clinic.
Discovery and/or validation of genetic signatures predictive of response (HuSignature™) and predictive biomarkers (HuMark™), therefore generating hypotheses for clinical testing.